Chondrial Therapeutics is pleased to announce several development milestones. Update 05.15

Chondrial Therapeutics is pleased to announce several development milestones. Update 05.15.

May 1, 2015

Chondrial Therapeutics is pleased to announce several development milestones. The company has successfully manufactured its lead commercial drug candidate for Friedreich’s Ataxia. It has also initiated preclinical validation studies and preliminary results are very encouraging. The company plans on pre-IND discussions later this year and conducting GLP Toxicology studies early next year.